The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma
Completed · Phase 1 · Has a placebo group
Conditions studied: Asthma
In brief
This study will determine if airway antioxidant levels in allergic asthmatics are enhanced with a combination of vitamin E and vitamin C therapy.
Key facts
- Study ID
- NCT00142610
- Run by
- University of North Carolina, Chapel Hill
- People needed
- 16
- Starts
- 2005-08-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2013-03-04
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed allergy to at least one of the following allergen preparations: house dust mite f; house dust mite p; cockroach; tree mix; grass mix; weed mix; mold mix 1; mold mix 2; rat; mouse; guinea pig; rabbit; cat; or dog
- Oxygen saturation greater than 94% at baseline
- Systolic blood pressure between 150 and 90 mm Hg, diastolic blood pressure between 90 and 60 mm Hg
- Physician-diagnosed asthma or history of episodic wheezing, chest tightness, or shortness of breath consistent with asthma
- Airway reactivity as determined by either a provocative concentration of methacholine producing a 20% fall in FEV1 (PC20 methacholine) of less than 10 mg/ml by the method used or 12% reversibility of baseline lung function with albuterol therapy for two of the three measures: FVC, FEV1, and FEF25-75%
- Agree to discontinue use of vitamin supplements for the duration of the study
- On a stable regimen of maintenance asthma therapy that has not changed within the month prior to participation
You may not qualify if…
- Chronic medical condition that may make vitamin E and vitamin C treatment medically inadvisable (e.g., significant cardiovascular disease, diabetes requiring medication, chronic kidney disease, chronic thyroid disease, or coagulation defects)
- History of kidney stones
- Use of anticoagulants (e.g., warfarin, heparin, or clopindogrel)
- Pregnant or breastfeeding
- Use of inhaled steroids, cromolyn, or leukotriene inhibitors (Montelukast or Zafirkulast) for at least one month is not criteria for exclusion.
Where it is running
- UNC EPA — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.